Communiqués Zai Lab Limited Börse Stuttgart

Actions

1ZL

US98887Q1040

Produits pharmaceutiques

Marché Fermé - Börse Stuttgart 21:56:00 18/08/2026			Varia. 5j.	Varia. 1 janv.
22,00 ^EUR	0,00%		+8,91%	+48,65%

17/08	Argenx annonce des résultats préliminaires positifs pour l'étude de phase 3 Alkivia sur l'efgartigimod dans la myosite auto-immune	CI
13/08	Légère hausse pour les actions asiatiques cotées aux États-Unis sous forme d'ADR lors de la séance de jeudi	MT

Communiqués

17/08	Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis	BU
06/08	Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates	BU
03/08	U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)	BU
22/07	Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026	BU
17/06	Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan in Pulmonary Neuroendocrine Carcinomas	AQ
16/06	Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas	BU
09/06	Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer	BU
22/05	Zai Lab Announces Changes to Senior Leadership Team	BU
11/05	Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)	BU
07/05	Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates	BU
22/04	Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026	BU
20/04	Zai Lab : AACR IR Presentation vFINAL	PU
18/04	Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases	BU
17/04	Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas	BU
01/04	Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy	BU
17/03	Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)	BU
26/02	Zai Lab : ZLAB 4Q25 Corporate Presentation EN vf	PU
26/02	Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates	BU
10/02	Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026	BU
13/01	Zai Lab : JPM 2026 Presentation vFinal	PU
13/01	Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference	BU
06/01	Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors	BU
05/01	Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference	BU
23/12	Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia	BU
08/12	Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis	BU